NEW YORK, May 2, 2017 /PRNewswire/ -- Kaplan Fox &
Kilsheimer LLP (www.kaplanfox.com) is investigating claims
on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular Therapies" or the "Company") (NASDAQ: ITCI).
Investors who purchased shares of Intra-Cellular common stock may be affected.
On May 1, 2017 before the market opened, Intra-Cellular Therapies issued a press release
reporting that as part of its ongoing dialogue with the U.S. Food and Drug Administration (FDA), the FDA "raised questions . . .
relating to certain findings observed in nonclinical animal toxicology studies" of lumateperone, the Company's proposed
schizophrenia treatment. Additionally, the FDA "requested additional information to confirm that the nonclinical findings
are not indicative of a safety risk associated with long-term exposure in humans."
Following this news, on May 1, 2017, the price of Intra-Cellular Therapies' common stock fell by
$3.33 per share, more than 24%, to close at $10.49 per share.
If you are an investor in Intra-Cellular Therapies and would like to discuss our investigation, please contact us by emailing
pmayer@kaplanfox.com or by calling
800-290-1952.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical
rules.
Kaplan Fox & Kilsheimer LLP, with offices in New York,
San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting
investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit
our website at www.kaplanfox.com. If you have any
questions about this Notice, the action, your rights, or your interests, please contact:
Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: dhall@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400
San Francisco, California 94104
(415) 772-4700
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/investor-alert-kaplan-fox-announces-investigation-of-intra-cellular-therapies-inc-300449856.html
SOURCE Kaplan Fox & Kilsheimer LLP